We observed the enhanced efficacy of CD33‐targeting RBCEVs loaded with ASOs in suppressing oncogenic FLT3‐ITD or miR‐125b levels in AML cells in vitro, resulting in a decreased cell viability. This evidence concerns the gene FLT3 and acute myeloid leukemia.